vs
Side-by-side financial comparison of BYLINE BANCORP, INC. (BY) and PTC THERAPEUTICS, INC. (PTCT). Click either name above to swap in a different company.
PTC THERAPEUTICS, INC. is the larger business by last-quarter revenue ($164.7M vs $112.4M, roughly 1.5× BYLINE BANCORP, INC.). BYLINE BANCORP, INC. runs the higher net margin — 33.4% vs -82.0%, a 115.4% gap on every dollar of revenue. On growth, BYLINE BANCORP, INC. posted the faster year-over-year revenue change (9.0% vs -22.7%). Over the past eight quarters, BYLINE BANCORP, INC.'s revenue compounded faster (6.4% CAGR vs -11.5%).
Byline Bank is a bank headquartered in Chicago, Illinois, United States. It is the primary subsidiary of Byline Bancorp, Inc., a bank holding company, and the 4th largest SBA 7(a) lender.
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.
BY vs PTCT — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $112.4M | $164.7M |
| Net Profit | $37.6M | $-135.0M |
| Gross Margin | — | — |
| Operating Margin | — | -43.3% |
| Net Margin | 33.4% | -82.0% |
| Revenue YoY | 9.0% | -22.7% |
| Net Profit YoY | 33.0% | -104.8% |
| EPS (diluted) | $0.83 | $-1.63 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $112.4M | — | ||
| Q4 25 | $117.0M | $164.7M | ||
| Q3 25 | $115.7M | $211.0M | ||
| Q2 25 | $110.5M | $178.9M | ||
| Q1 25 | $103.1M | $1.2B | ||
| Q4 24 | $104.7M | $213.2M | ||
| Q3 24 | $101.8M | $196.8M | ||
| Q2 24 | $99.4M | $186.7M |
| Q1 26 | $37.6M | — | ||
| Q4 25 | $34.5M | $-135.0M | ||
| Q3 25 | $37.2M | $15.9M | ||
| Q2 25 | $30.1M | $-64.8M | ||
| Q1 25 | $28.2M | $866.6M | ||
| Q4 24 | $30.3M | $-65.9M | ||
| Q3 24 | $30.3M | $-106.7M | ||
| Q2 24 | $29.7M | $-99.2M |
| Q1 26 | — | — | ||
| Q4 25 | 40.1% | -43.3% | ||
| Q3 25 | 43.1% | 1.4% | ||
| Q2 25 | 35.2% | -19.5% | ||
| Q1 25 | 36.4% | 82.5% | ||
| Q4 24 | 38.6% | -76.2% | ||
| Q3 24 | 39.3% | -27.7% | ||
| Q2 24 | 40.4% | -21.5% |
| Q1 26 | 33.4% | — | ||
| Q4 25 | 34.1% | -82.0% | ||
| Q3 25 | 32.1% | 7.5% | ||
| Q2 25 | 27.2% | -36.3% | ||
| Q1 25 | 27.4% | 73.7% | ||
| Q4 24 | 34.3% | -30.9% | ||
| Q3 24 | 29.8% | -54.2% | ||
| Q2 24 | 29.9% | -53.1% |
| Q1 26 | $0.83 | — | ||
| Q4 25 | $0.77 | $-1.63 | ||
| Q3 25 | $0.82 | $0.20 | ||
| Q2 25 | $0.66 | $-0.83 | ||
| Q1 25 | $0.64 | $10.04 | ||
| Q4 24 | $0.68 | $-0.85 | ||
| Q3 24 | $0.69 | $-1.39 | ||
| Q2 24 | $0.68 | $-1.29 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $198.4M | $1.9B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.3B | $-205.3M |
| Total Assets | $9.9B | $2.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $198.4M | — | ||
| Q4 25 | $149.1M | $1.9B | ||
| Q3 25 | $259.0M | $1.7B | ||
| Q2 25 | $218.3M | $2.0B | ||
| Q1 25 | $421.3M | $2.0B | ||
| Q4 24 | $563.1M | $1.1B | ||
| Q3 24 | $452.6M | $1.0B | ||
| Q2 24 | $730.5M | $1.1B |
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $-205.3M | ||
| Q3 25 | $1.2B | $-155.8M | ||
| Q2 25 | $1.2B | $-206.5M | ||
| Q1 25 | $1.1B | $-185.8M | ||
| Q4 24 | $1.1B | $-1.1B | ||
| Q3 24 | $1.1B | $-1.1B | ||
| Q2 24 | $1.0B | $-980.2M |
| Q1 26 | $9.9B | — | ||
| Q4 25 | $9.7B | $2.9B | ||
| Q3 25 | $9.8B | $2.6B | ||
| Q2 25 | $9.7B | $2.6B | ||
| Q1 25 | $9.6B | $2.7B | ||
| Q4 24 | $9.5B | $1.7B | ||
| Q3 24 | $9.4B | $1.8B | ||
| Q2 24 | $9.6B | $1.9B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-34.3M |
| Free Cash FlowOCF − Capex | — | $-36.6M |
| FCF MarginFCF / Revenue | — | -22.3% |
| Capex IntensityCapex / Revenue | — | 1.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $702.3M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $140.3M | $-34.3M | ||
| Q3 25 | $38.3M | $-66.3M | ||
| Q2 25 | $16.3M | $-58.3M | ||
| Q1 25 | $27.1M | $870.1M | ||
| Q4 24 | $175.2M | $-30.0M | ||
| Q3 24 | $19.8M | $-77.0M | ||
| Q2 24 | $40.1M | $-71.5M |
| Q1 26 | — | — | ||
| Q4 25 | $136.3M | $-36.6M | ||
| Q3 25 | $38.0M | $-69.7M | ||
| Q2 25 | $15.2M | $-59.6M | ||
| Q1 25 | $25.0M | $868.4M | ||
| Q4 24 | $171.2M | $-33.8M | ||
| Q3 24 | $19.1M | $-77.5M | ||
| Q2 24 | $39.4M | $-78.8M |
| Q1 26 | — | — | ||
| Q4 25 | 116.5% | -22.3% | ||
| Q3 25 | 32.8% | -33.1% | ||
| Q2 25 | 13.7% | -33.3% | ||
| Q1 25 | 24.3% | 73.8% | ||
| Q4 24 | 163.5% | -15.8% | ||
| Q3 24 | 18.8% | -39.4% | ||
| Q2 24 | 39.7% | -42.2% |
| Q1 26 | — | — | ||
| Q4 25 | 3.4% | 1.4% | ||
| Q3 25 | 0.3% | 1.6% | ||
| Q2 25 | 1.0% | 0.7% | ||
| Q1 25 | 2.0% | 0.1% | ||
| Q4 24 | 3.8% | 1.8% | ||
| Q3 24 | 0.6% | 0.3% | ||
| Q2 24 | 0.7% | 4.0% |
| Q1 26 | — | — | ||
| Q4 25 | 4.06× | — | ||
| Q3 25 | 1.03× | -4.17× | ||
| Q2 25 | 0.54× | — | ||
| Q1 25 | 0.96× | 1.00× | ||
| Q4 24 | 5.78× | — | ||
| Q3 24 | 0.65× | — | ||
| Q2 24 | 1.35× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
